Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43926616" target="_blank" >RIV/00064173:_____/24:43926616 - isvavai.cz</a>

Alternative codes found

RIV/68407700:21460/24:00375764 RIV/00216208:11120/24:43926616 RIV/00098892:_____/24:10158630 RIV/00023001:_____/24:00084687 RIV/60076658:12110/24:43908584

Result on the web

<a href="https://doi.org/10.1093/europace/euae040" target="_blank" >https://doi.org/10.1093/europace/euae040</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/europace/euae040" target="_blank" >10.1093/europace/euae040</a>

Result language

angličtina

Original language name

Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

Original language description

BACKGROUND AND AIMS: Data on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS: The trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation (Hybrid Group) or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalisation for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. RESULTS: We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the Hybrid Group (41.1% vs 67.4%, hazard ratio (HR)=0.38, 95% confidence interval (CI): 0.26-0.57, P&lt;0.001) as well as the primary clinical endpoint (19.9% vs 40.1%, HR=0.51, 95% CI: 0.29-0.86, P=0.012). The trial groups did not differ in all-cause mortality (10.6% vs 8.6%, HR=1.17, 95%CI: 0.51-2.71, P=0.71). The major complications of catheter ablation were infrequent (1.9%). CONCLUSIONS: Pre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

<a href="/en/project/NV19-02-00046" target="_blank" >NV19-02-00046: Sequential Hybrid Ablation versus Surgical CryoMaze Alone for Treatment of Atrial Fibrillation (SurHyb Trial): a multicenter randomized controlled trial</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Europace

ISSN

1099-5129

e-ISSN

1532-2092

Volume of the periodical

26

Issue of the periodical within the volume

2

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

"euae040"

UT code for WoS article

001163513100002

EID of the result in the Scopus database

2-s2.0-85185277401